CDX2 and ampulla of vater adenocarcinoma: Kapp et al11 from Germany retrospectively reported an exceptional response to nab‐paclitaxel and gemcitabine in 1 patient with refractory ampullary adenocarcinoma whose tumor IHC staining pattern was CK7‐positive and CK20‐ and CDX2‐negative.